DR.Jignesh Gala retina eye surgeon

Diabetic Retinopathy Specialist in Andheri — Sugar, Sight & the Screening Schedule That Saves Vision

/ Retina Services / By

Diabetic Retinopathy Specialist in Andheri — Sugar, Sight & the Screening Schedule That Saves Vision

Written & medically reviewed by Dr. Jignesh Gala, Vitreoretinal & Cataract Surgeon (FRCS Glasgow), Founder & Director — Crystal Clear Eye Clinic (Andheri West) and Topax Eye Hospital (Vile Parle East), Mumbai. Facts verified: 24 July 2026.

Thank you for reading this post, don't forget to subscribe!

⚡ Quick answer: Diabetic retinopathy is damage to the retina’s blood vessels from years of high sugar — early on it causes zero symptoms, which is why it blinds people who “felt fine.” Every diabetic needs a dilated retina check yearly even with perfect vision, and every 3–6 months once disease is found. Treatment in 2026 works well on time: anti-VEGF injections (₹8,000–38,000 by drug), PRP laser (₹3,000–8,000/sitting), vitrectomy for advanced disease. Searching for a diabetic retinopathy specialist in Andheri? Dr. Jignesh Gala (FRCS Glasgow) treats diabetic eyes at Crystal Clear Eye Clinic, Andheri West and Topax Eye Hospital, Vile Parle East. Call 077188 85245.

🔎 Popular guides by Dr. Gala:

1. The 4 Stages of Diabetic Retinopathy

High blood sugar slowly chokes the tiny vessels feeding your retina — the “film” at the back of the eye. First the walls weaken and leak, then vessels close off, and finally the starving retina grows new, fragile vessels that bleed. Your stage matters because each has its own schedule and its own treatment:

StageWhat Is Happening InsideWhat You FeelWhat It Needs
1. Mild NPDRMicroaneurysms — tiny bulges in vessel wallsNothingYearly dilated check + tight sugar/BP control
2. Moderate NPDRMore leaks and blockages; small haemorrhagesUsually nothingCheck every 6 months; treat DME if present
3. Severe NPDRLarge retinal areas losing blood supplyOften still nothing — the danger zoneEvery 3–4 months; laser/injections likely
4. PDR (proliferative)New abnormal vessels grow, bleed, pull the retina offFloaters, sudden vision lossUrgent PRP laser and/or anti-VEGF; vitrectomy if bleeding/detachment

One complication can strike at any stage: diabetic macular oedema (DME) — fluid in the macula, the retina’s sharp-vision centre — can appear at any stage, mild included, and is today’s commonest cause of vision loss in working-age diabetics. So a competent diabetic retinopathy specialist in Andheri never grades you from a quick look — stage, macula status on OCT and leakage pattern together decide your plan. For the wider picture, see retina treatment in Andheri.

Diabetic retinopathy specialist in Andheri — dilated retina examination at Crystal Clear Eye Clinic, Andheri West, Mumbai
Dilated retinal examination at Crystal Clear Eye Clinic, Andheri West — the yearly habit that saves diabetic vision.

2. The Screening Schedule That Saves Vision

The uncomfortable truth: “my vision is fine” means nothing. The retina can quietly haemorrhage for years while you read WhatsApp perfectly. By the time vision blurs, disease is often advanced — harder, costlier, with less vision recovered. Screening catches it where treatment is cheapest and most effective.

The schedule we follow:

  • Retina normal: dilated examination once a year — type 1 starts within 5 years of diagnosis, type 2 from day one.
  • Mild/moderate NPDR: every 6 months, with OCT if the macula is involved.
  • Severe NPDR / early PDR: every 3–4 months — waiting “one more year” here costs vision.
  • On anti-VEGF injections: every 4–8 weeks — the effect is measured in weeks, not months.
  • Pregnancy with diabetes: check each trimester — pregnancy can accelerate retinopathy.
OCT screening for diabetic retinopathy in Andheri — retinal scan reviewed by diabetic retinopathy specialist Dr Jignesh Gala, Mumbai
OCT screening — a 5-minute, painless scan that detects macular oedema before vision drops.

A proper screening visit is more than a glance through a lens: vision, eye pressure, dilated retinal examination, and — when indicated — OCT (₹1,500–3,000/eye) or OCT angiography (₹3,500–5,000) to map leakage without dye. Consultation runs ₹800–1,500 (verified 24 July 2026). For the full picture, read about retina treatment in Mumbai — advanced retinal care.

Real-world advice: put your retina check in the same calendar as your HbA1c. Diabetics across Lokhandwala, Versova, Juhu, Oshiwara and DN Nagar who test sugar quarterly but skip the dilated eye exam are guarding the kidneys while leaving the eyes exposed. Check both.

3. The 3 Weapons: Anti-VEGF Injections, PRP Laser, Vitrectomy

When diabetic retinopathy needs active treatment, a retina specialist has three proven weapons — the art is choosing the right one for your stage, and combining them when needed:

Weapon 1 — Anti-VEGF Injections (the fluid-dryers)

Diabetic eyes produce excess VEGF, a chemical that makes vessels leak and sprout. Anti-VEGF drugs (ranibizumab, aflibercept/Eylea, faricimab, biosimilars) are injected after numbing drops — a 2-minute procedure, repeated every 4–8 weeks initially, then stretched as the retina dries. First-line for diabetic macular oedema and a powerful PDR option. Mumbai 2026: ₹8,000–38,000 per injection by drug (Eylea MRP ₹29,998 after the April-2026 cut). Courses are long-term — see our surgery packages philosophy.

Weapon 2 — PRP Laser (the vessel-shrinker)

PRP applies hundreds of tiny laser burns to the oxygen-starved peripheral retina, switching off the VEGF factory at its source. It remains the bedrock of PDR treatment — proven for decades (PRP evidence, Cochrane review) and refined by modern techniques (techniques review). Cost: ₹3,000–8,000 per sitting, usually 2–3 per eye. Honest caveat: PRP is not “1 and done” — eyes can reactivate years later (RIDE/RISE analysis). Details: retina laser treatment in Andheri West — PRP, barrage, focal & micropulse.

Weapon 3 — Vitrectomy (the rescue surgery)

When PDR has caused non-clearing vitreous haemorrhage or tractional detachment, micro-incision vitrectomy removes blood and scar tissue and completes laser from inside — sutureless day-care surgery, typically ₹40,000–1,50,000 in Mumbai. A 2021 network meta-analysis (Acta Ophthalmologica) and a 2025 systematic review (Ophthalmology Retina) show injections give faster visual results while PRP gives more durable control — we often combine both. Our guide to retina surgery in Mumbai explains what to expect.

For diabetics who also have cataract or glasses dependence: lens choices need retinal clearance first. Once your retina is stable, explore types of intraocular lenses, refractive lens exchange (RLE), RLE vs LASIK, and SmartSurf with CustomEyes glass removal surgery. Sequence matters: retina first, always.

4. Sugar, BP, Kidneys — The Other Half of Treatment

Every injection and laser only wins you time; what you do with that time decides the result. Diabetic retinopathy has two arms — the eye arm (our job) and the body arm (yours and your diabetologist’s):

  • HbA1c below 7% for most adults — each 1% drop cuts progression risk by roughly a third. Caution: a sudden HbA1c crash can temporarily worsen retinopathy; we coordinate timing with your physician.
  • Blood pressure below 140/90 — uncontrolled BP can undo a good injection’s work in weeks.
  • Kidneys and eyes are twins: urine protein and retinopathy rise together. If one is found, screen the other — and keep both specialists informed.
  • Cholesterol and smoking: statins reduce macular hard exudates; smoking accelerates every stage.
  • Teamwork by design: Dr. Gala writes to your diabetologist after key visits. Patients from Jogeshwari, Goregaon, Malad, Kandivali, Bandra, Khar and Santacruz — bring your reports; we read them all.

5. Why Patients Choose Dr. Jignesh Gala as Their Diabetic Retinopathy Specialist in Andheri

Dr Jignesh Gala — diabetic retinopathy specialist in Andheri West, Mumbai at Crystal Clear Eye Clinic
Dr. Jignesh Gala, FRCS (Glasgow) — vitreoretinal surgeon for diabetic eye disease in Andheri West

Dr. Jignesh Gala is a vitreoretinal & cataract surgeon — FRCS (Glasgow), MRCS (Edinburgh), FICO — with a dedicated vitreoretinal fellowship from L.V. Prasad Eye Institute, India’s most respected retina training ground. He owns and directs both Crystal Clear Eye Clinic (Andheri West) and Topax Eye Hospital (Vile Parle East) — screening, injections, laser and surgery all stay with one accountable specialist.

✅ Retina is his sub-speciality, not a side practice: years operating on diabetic haemorrhages and detachments means he knows which early lesions will misbehave — and which can be safely watched.

✅ International grounding: founding ophthalmology team of Woodlands Health, Singapore — read his Singapore 2021 account — and ex-Assistant Professor, B.Y.L. Nair Hospital, Mumbai.

✅ Fully aware of the latest research — unlike old practitioners who stopped reading journals years ago: six years as a BMJ Case Reports peer reviewer keeps his thresholds aligned with 2026 evidence.

✅ You see the work, not just the claims: real outcomes in satisfied patient stories and unedited procedures in surgical videos by Dr. Jignesh Gala.

✅ Honest scheduling: if your retina only needs a yearly check, you will be told that — not sold a package.

6. Locations — Diabetic Retinopathy Specialist in Andheri West & Vile Parle East

1) Crystal Clear Eye Clinic — Andheri West

📍 Address: Laram Centre CHS, A1-202, Swami Vivekanand Road, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai 400058 • Open daily, closes 9 pm.
📞 Phone: 077188 85245 • 💬 WhatsApp Us
💳 Third-party/TPA cashless is done through Crystal Clear Eye Clinic (Andheri West).

Minutes from Andheri station, Lokhandwala, Versova, Yari Road, Juhu, Oshiwara, DN Nagar, Seven Bungalows, Azad Nagar, Veera Desai Road, Jogeshwari and Amboli; Bandra, Khar, Santacruz, Goregaon, Malad and Kandivali reach us in 20–30 minutes.

Diabetic retina care team at Topax Eye Hospital Vile Parle East — diabetic retinopathy specialist near Andheri Mumbai
The Topax Eye Hospital team, Vile Parle East — injections, PRP laser and vitrectomy under one roof.

2) Topax Eye Hospital — Vile Parle East

📍 Vile Parle East, Mumbai (call for the exact address & directions) • 📞 077188 85245 • Open daily, closes 9 pm.
💳 Direct cashless is done through Topax Eye Care (Vile Parle East).

Convenient for Santacruz East, Khar, Bandra East, Kalina, Vakola, Juhu and the airport corridor. As a full hospital, Topax handles the whole diabetic retinopathy journey — OCT, injections, PRP laser, vitrectomy — under Dr. Gala himself.

7. हिंदी • मराठी • ગુજરાતી — Patient Summaries

🇮🇳 हिंदी सारांश — डायबिटिक रेटिनोपैथी

डायबिटीज़ (शुगर) आँख के रेटिना की नसों को चुपचाप नुकसान पहुँचाती है — शुरुआत में कोई लक्षण नहीं। इसलिए हर डायबिटिक को साल में एक बार पुतली फैलाकर रेटिना जाँच करानी चाहिए। इलाज: anti-VEGF इंजेक्शन, PRP लेज़र और ज़रूरत पर विट्रेक्टमी सर्जरी। अंधेरी में डायबिटिक रेटिनोपैथी स्पेशलिस्ट डॉ. जिग्नेश गाला (FRCS ग्लासगो) — क्रिस्टल क्लियर आई क्लिनिक, अंधेरी वेस्ट और टोपैक्स आई हॉस्पिटल, विले पार्ले ईस्ट। अपॉइंटमेंट: 077188 85245।

🚩 मराठी सारांश — डायबिटिक रेटिनोपथी

मधुमेहामुळे रेटिनाच्या रक्तवाहिन्या हळूहळू खराब होतात — सुरुवातीला दृष्टी व्यवस्थित असूनही नुकसान सुरू असते. म्हणून प्रत्येक मधुमेह रुग्णाने दरवर्षी रेटिना तपासणी करावी. उपचार: इंजेक्शन, PRP लेझर आणि गरजेनुसार विट्रेक्टमी शस्त्रक्रिया. अंधेरीत डायबिटिक रेटिनोपथी तज्ज्ञ डॉ. जिग्नेश गाला — क्रिस्टल क्लियर आय क्लिनिक, अंधेरी वेस्ट व टोपॅक्स आय हॉस्पिटल, विले पार्ले ईस्ट. भेटीसाठी: 077188 85245.

🟡 ગુજરાતી સારાંશ — ડાયાબિટિક રેટિનોપેથી

ડાયાબિટીઝ (સુગર) રેટિનાની નસોને ધીમે ધીમે નુકસાન કરે છે — શરૂઆતમાં કોઈ લક્ષણ દેખાતું નથી. એટલે દરેક ડાયાબિટિકે વર્ષમાં એક વાર રેટિના તપાસ કરાવવી જોઈએ. સારવાર: ઇન્જેક્શન, PRP લેઝર અને જરૂર પડે તો વિટ્રેક્ટમી સર્જરી. અંધેરીમાં ડાયાબિટિક રેટિનોપેથી સ્પેશિયાલિસ્ટ ડૉ. જિગ્નેશ ગાલા — ક્રિસ્ટલ ક્લિયર આય ક્લિનિક, અંધેરી વેસ્ટ અને ટોપેક્સ આય હોસ્પિટલ, વિલે પાર્લે ઇસ્ટ. એપોઈન્ટમેન્ટ: 077188 85245.

Dr Jignesh Gala in scrubs — diabetic retinopathy specialist in Andheri performing retinal laser and injection treatment Mumbai
Every injection and laser for diabetic eye disease is performed by Dr. Gala himself — never delegated.

8. ❓ 8 Frequently Asked Questions (English + Hinglish)

1. Diabetic retinopathy kya hoti hai?

Diabetes mein zyada sugar retina ki patli khoon ki naliyon ko dheere dheere kharab karta hai — pehle leak, phir blockage, phir nayi kamzor nalkiyan jo khoon beha sakti hain. Khatarnak baat — shuru mein koi lakshan nahi hote. Isliye har diabetic ko saal mein ek baar dilated retina check-up zaroori hai, chahe nazar theek ho.

2. Diabetes mein aankh ka check-up kitni baar karana chahiye?

Retina normal hai toh saal mein ek baar. Mild/moderate retinopathy par har 6 mahine, severe par har 3–4 mahine, injection chal rahe hon toh har 4–8 hafte. Pregnancy mein har trimester. “Meri nazar theek hai” keh kar check-up talna hi sabse badi galti hai.

3. Diabetic retinopathy treatment cost in Mumbai kitna hai?

Mumbai 2026 ranges (verified 24 July 2026): consultation ₹800–1,500; OCT ₹1,500–3,000/eye; anti-VEGF injection ₹8,000–38,000 drug ke hisaab se (Eylea MRP ₹29,998 after April-2026 cut); PRP laser ₹3,000–8,000/sitting; vitrectomy ₹40,000–1,50,000. Exact pricing ke liye call 077188 85245.

4. Kya diabetic retinopathy cure ho sakti hai?

Sach: poori tarah “cure” nahi hoti — diabetes jab tak hai, asar wapas aa sakta hai. Lekin sahi waqt par ilaaj se disease control aur stall ho jaati hai — DME ka paani sukhta hai, PDR ke vessels regress hote hain, vision sambhal jaati hai. Injection-laser waqt jeetate hain; sugar-BP-kidney control use zindagi bhar banaye rakhte hain.

5. Sugar control karne se retina theek ho jata hai kya?

Sugar control progression ko bahut slow karta hai — HbA1c 7% se neeche rakhna sabse powerful “treatment” hai. Lekin jo damage ho chuka hai wo sirf sugar theek karne se reverse nahi hota — uske liye injection ya laser chahiye. Tezi se HbA1c girane par retinopathy temporarily badh sakti hai, isliye hum aapke diabetologist ke saath milkar kaam karte hain.

6. Diabetic eye injection dardnak hota hai kya?

Nahi — yeh sabse common dar hai aur bilkul bebuniyad. Numbing drops ke baad 2-minute ka procedure hota hai; zyada tar patients sirf halka pressure mehsoos karte hain, dard nahi. Usi din ghar ja sakte hain. Sach ye hai: patients ko procedure se zyada procedure ke khayal se dar lagta hai.

7. Diabetic retinopathy specialist kahan hain Andheri mein?

Dr. Jignesh Gala (FRCS Glasgow) — Crystal Clear Eye Clinic, Laram Centre CHS, A1-202, S.V. Road, above Sunil Jewellers, near NADCO Shopping Centre, Andheri West 400058; ya Topax Eye Hospital, Vile Parle East. Phone same hai: 077188 85245. Open daily, closes 9 pm. Screening se surgery tak — sab ek hi specialist ke haath mein.

8. Which is better for diabetic eyes – injection or laser?

They treat different problems — the honest answer is “it depends on your stage.” For diabetic macular oedema, anti-VEGF injections are first-line. For PDR, PRP gives durable control while injections work faster but need repetition; we often combine both. The “better” choice is made after examining your retina and OCT — that personalised call is what a specialist visit is for.

Every guide below is written by the same surgeon who would operate on you:

From drjigneshgalaeye.com

From crystalcleareye.in

Your retina deserves a specialist. Today, not someday.

Diabetes will be with you for life. So should a retina specialist who tracks your eyes on a schedule — not when symptoms shout.

📍 Andheri West: Laram Centre CHS, A1-202, S.V. Road, above Sunil Jewellers, near NADCO Shopping Centre, Mumbai 400058
📍 Vile Parle East: Topax Eye Hospital • Open daily, closes 9 pm

📞 Call 077188 85245 💬 WhatsApp Us

Dr. Jignesh Gala, FRCS (Glasgow) — Vitreoretinal & Cataract Surgeon • drjigneshgalaeye.com • crystalcleareye.in

Medical disclaimer: This page is educational and does not replace a personal consultation. Prices are indicative, verified on 24 July 2026, and may change. Every eye is different — decisions are made only after examination by Dr. Jignesh Gala.

Research & Evidence Library — 103 Verified References

Every link verified live in July 2026 (official NCBI E-utilities). This is the research Dr. Gala reads — click any title to verify the science yourself.

LASER: Panretinal Photocoagulation (Prp) For Pdr

  1. Panretinal photocoagulation for proliferative diabetic retinopathy. — The New England journal of medicine, 2011
  2. Laser photocoagulation for proliferative diabetic retinopathy. — The Cochrane database of systematic reviews, 2014
  3. Different lasers and techniques for proliferative diabetic retinopathy. — The Cochrane database of systematic reviews, 2018
  4. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not “1 and Done”. — Ophthalmology, 2021
  5. Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy – a systematic review and network meta-analysis. — Acta ophthalmologica, 2021
  6. Anti-VEGF Injections vs. Panretinal Photocoagulation Laser Therapy for Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis. — Ophthalmology. Retina, 2025
  7. Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy. — JAMA ophthalmology, 2024

LASER: Landmark Trials: Drs & Etdrs

  1. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. — Archives of ophthalmology (Chicago, Ill. : 1960), 1985
  2. Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12. — Ophthalmology, 1987
  3. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS Report Number 2. — Ophthalmology, 1987
  4. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. — Ophthalmology, 1991
  5. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. — Ophthalmology, 1991
  6. Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. ETDRS report number 10. — Ophthalmology, 1991
  7. Focal photocoagulation treatment of diabetic macular edema. ETDRS report no. 19. — Archives of ophthalmology (Chicago, Ill. : 1960), 1995
  8. The Early Treatment Diabetic Retinopathy Study historical review and relevance to today’s management of diabetic macular edema. — Current opinion in ophthalmology, 2017

LASER: Focal / Grid Laser For Diabetic Macular Edema

  1. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. — Retina (Philadelphia, Pa.), 2009
  2. Indocyanine Green Angiography-Guided Focal Laser Photocoagulation for Diabetic Macular Edema. — Ophthalmologica, 2015
  3. Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review. — Journal of ophthalmology, 2017
  4. Monotherapy laser photocoagulation for diabetic macular oedema. — The Cochrane database of systematic reviews, 2018
  5. How do we evaluate the role of focal/grid photocoagulation in the treatment of diabetic macular edema? — Acta ophthalmologica, 2019
  6. Functional and structural efficacy of a novel combinational therapy of aflibercept and timely focal/grid photocoagulation in centre-involving diabetic macular oedema: the TAFI study. — Acta ophthalmologica, 2022
  7. The Role of Laser Photocoagulation in Treating Diabetic Macular Edema in the Era of Intravitreal Drug Administration: A Narrative Review. — Medicina (Kaunas, Lithuania), 2023

LASER: Anti-Vegf Vs Laser (Clarity, Protocol S)

  1. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (CLARITY): study protocol. — BMJ open, 2015
  2. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. — JAMA, 2015
  3. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a phase 2b non-inferiority trial. — Lancet (London, England), 2017
  4. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy. — JAMA ophthalmology, 2018
  5. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating PDR: A Secondary Analysis. — JAMA ophthalmology, 2019
  6. Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in PDR: Post Hoc Analysis of CLARITY. — JAMA ophthalmology, 2021
  7. Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of DRCR Protocol S. — Current opinion in ophthalmology, 2024

IVT: Ranibizumab For Diabetic Macular Edema

  1. Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. — Survey of ophthalmology, 2023
  2. Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes. — Developments in ophthalmology, 2017
  3. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema. — Ophthalmology. Retina, 2020
  4. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. — International journal of molecular sciences, 2022
  5. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis. — Advances in therapy, 2023
  6. Diabetic macular edema. — Developments in ophthalmology, 2010
  7. Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials. — Retina (Philadelphia, Pa.), 2014
  8. Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis. — JAMA ophthalmology, 2025
  9. [Recommendations for the use of ranibizumab in diabetic macular edema at IMSS]. — Revista medica del Instituto Mexicano del Seguro Social, 2017
  10. Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis. — Ophthalmology. Retina, 2023

IVT: Aflibercept For Diabetic Macular Edema

  1. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. — Ophthalmology, 2024
  2. IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS. — Retina (Philadelphia, Pa.), 2025
  3. Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis. — European journal of ophthalmology, 2024
  4. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. — Ophthalmology, 2016
  5. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. — Current opinion in ophthalmology, 2025
  6. Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. — Ophthalmology, 2026
  7. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. — Lancet (London, England), 2024
  8. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. — The New England journal of medicine, 2022
  9. Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. — Ophthalmology. Retina, 2025
  10. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). — Ophthalmology, 2020

EYLEA: Vivid & Vista — Diabetic Macular Edema

  1. Intravitreal aflibercept for diabetic macular edema. — Ophthalmology, 2014
  2. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. — Ophthalmology, 2015
  3. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. — Ophthalmology, 2016
  4. Time to Resolution of Diabetic Macular Edema after Treatment with Intravitreal Aflibercept Injection or Laser in VISTA and VIVID. — Ophthalmology. Retina, 2023
  5. INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES. — Retina (Philadelphia, Pa.), 2023

EYLEA: Clarity & Panorama — Diabetic Retinopathy

  1. Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy. — Investigative ophthalmology & visual science, 2018
  2. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. — JAMA ophthalmology, 2021
  3. Consistency of Treatment Effect with Aflibercept by Baseline Factors in PANORAMA. — Ophthalmology. Retina, 2023

OCT: Diabetic Macular Edema Biomarkers

  1. Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers — Survey of ophthalmology, 2024
  2. Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis — Ophthalmology, 2026
  3. Optical coherence tomography in the management of diabetic macular oedema — Progress in retinal and eye research, 2024
  4. Imaging and Biomarkers in Diabetic Macular Edema and Diabetic Retinopathy — Current diabetes reports, 2019

OCT: Oct Angiography In Diabetic Retinopathy

  1. OCT angiography 2023 update: focus on diabetic retinopathy — Acta diabetologica, 2024
  2. New insights into diabetic retinopathy by OCT angiography — Diabetes research and clinical practice, 2018
  3. Optical coherence tomography angiography in diabetic retinopathy: an updated review — Eye (London, England), 2021
  4. Association of OCT Angiography-Detected Intraretinal Microvascular Abnormalities with Diabetic Retinopathy Severity — Ophthalmology. Retina, 2026
  5. COMPARATIVE ANALYSIS OF OCT AND OCT ANGIOGRAPHY CHARACTERISTICS IN EARLY DIABETIC RETINOPATHY — Retina (Philadelphia, Pa.), 2023

OCT: Telemedicine / Screening For Diabetic Retinopathy

  1. Review of smartphone funduscopy for diabetic retinopathy screening — Survey of ophthalmology, 2024
  2. Comparison of Telemedicine Screening of Diabetic Retinopathy by Mydriatic Smartphone-Based vs Nonmydriatic Tabletop Camera-Based Fundus Imaging — Journal of vitreoretinal diseases, 2021
  3. The role of tele-ophthalmology in diabetic retinopathy screening — Journal of optometry, 2020
  4. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore — Ophthalmology, 2016
  5. Feasibility of telemedicine in detecting diabetic retinopathy and age-related macular degeneration — Seminars in ophthalmology, 2015

COST: Anti-Vegf Cost In India (Dme)

  1. Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population. — Clinical ophthalmology (Auckland, N.Z.), 2021
  2. Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema. — Indian journal of pharmacology, 2024
  3. Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact. — Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2017

COST: Treat-And-Extend Cost-Minimisation

  1. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration. — Graefe’s archive for clinical and experimental ophthalmology, 2022
  2. Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland. — Journal of medical economics, 2025
  3. A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands. — Graefe’s archive for clinical and experimental ophthalmology, 2025

COST: Treatment Burden & Indirect Costs

  1. Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration. — Acta ophthalmologica, 2024
  2. Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia. — Diabetes, metabolic syndrome and obesity : targets and therapy, 2019
  3. Optimizing the invisible costs of anti-VEGF: The road to regularity. — Indian journal of ophthalmology, 2026

HVFE: Glaucoma Visual Field Quality Of Life & Driving

  1. Visual disability and quality of life in glaucoma patients. — Progress in brain research, 2015
  2. Measuring Disability in Glaucoma. — Journal of glaucoma, 2018
  3. Clinical risk stratification in glaucoma. — Eye (London, England), 2023
  4. Quality of Life of Patients with Glaucoma in Slovakia. — International journal of environmental research and public health, 2021
  5. Association between visual field defects and quality of life in the United States. — Ophthalmology, 2014
  6. Visual function affects prosocial behaviors in older adults. — International ophthalmology, 2016
  7. Assessing Functional Disability in Glaucoma: The Relative Importance of Central Versus Far Peripheral Visual Fields. — Investigative ophthalmology & visual science, 2020
  8. The correlation between glaucomatous visual field loss and vision-related quality of life. — Journal of glaucoma, 2015

EYLEA: Protocol T — Aflibercept Vs Bevacizumab Vs Ranibizumab

  1. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. — The New England journal of medicine, 2015
  2. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. — JAMA ophthalmology, 2016
  3. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. — JAMA ophthalmology, 2017
  4. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. — Journal of medical economics, 2020

EYLEA: Safety

  1. Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials. — Ophthalmology, 2016
  2. Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS). — Frontiers in pharmacology, 2022
  3. Noninfectious Intraocular Inflammation After Intravitreal Aflibercept. — JAMA ophthalmology, 2025
  4. Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study. — Canadian journal of ophthalmology, 2026

LASER: Subthreshold Micropulse Laser

  1. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. — Retina (Philadelphia, Pa.), 2015
  2. Subthreshold Micropulse Laser for Diabetic Macular Edema: A Review. — Journal of clinical medicine, 2022
  3. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT. — Health technology assessment (Winchester, England), 2022
  4. Diabetic macular edema treatment with subthreshold micropulse laser – five-year long monitoring. — Biomedical papers, 2023
  5. Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a randomized clinical trial. — Graefe’s archive for clinical and experimental ophthalmology, 2024
  6. Settings and Clinical Applications of Subthreshold Micropulse Laser Therapy: A Review. — Journal of clinical medicine, 2024
  7. Response to subthreshold micropulse laser treatment in the prophylaxis of diabetic macular oedema: A preliminary study. — Acta ophthalmologica, 2026